KR101972990B1 - 단백질 키나제 저해제 - Google Patents

단백질 키나제 저해제 Download PDF

Info

Publication number
KR101972990B1
KR101972990B1 KR1020147036372A KR20147036372A KR101972990B1 KR 101972990 B1 KR101972990 B1 KR 101972990B1 KR 1020147036372 A KR1020147036372 A KR 1020147036372A KR 20147036372 A KR20147036372 A KR 20147036372A KR 101972990 B1 KR101972990 B1 KR 101972990B1
Authority
KR
South Korea
Prior art keywords
mmol
added
compound
reduced pressure
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147036372A
Other languages
English (en)
Korean (ko)
Other versions
KR20150015527A (ko
Inventor
알랭 로랑
야닉 로즈
제임스 비. 재퀴스
Original Assignee
파마사이언스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2779184A external-priority patent/CA2779184A1/en
Priority claimed from CA2813299A external-priority patent/CA2813299A1/en
Application filed by 파마사이언스 인크. filed Critical 파마사이언스 인크.
Publication of KR20150015527A publication Critical patent/KR20150015527A/ko
Application granted granted Critical
Publication of KR101972990B1 publication Critical patent/KR101972990B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020147036372A 2012-05-31 2013-05-28 단백질 키나제 저해제 Expired - Fee Related KR101972990B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA2779184A CA2779184A1 (en) 2012-05-31 2012-05-31 Protein kinase inhibitors
CA2,779,184 2012-05-31
CA2,813,299 2013-04-17
CA2813299A CA2813299A1 (en) 2013-04-17 2013-04-17 Protein kinase inhibitors
PCT/CA2013/000513 WO2013177668A1 (en) 2012-05-31 2013-05-28 Protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197011438A Division KR20190043648A (ko) 2012-05-31 2013-05-28 단백질 키나제 저해제

Publications (2)

Publication Number Publication Date
KR20150015527A KR20150015527A (ko) 2015-02-10
KR101972990B1 true KR101972990B1 (ko) 2019-04-26

Family

ID=49672221

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197011438A Ceased KR20190043648A (ko) 2012-05-31 2013-05-28 단백질 키나제 저해제
KR1020147036372A Expired - Fee Related KR101972990B1 (ko) 2012-05-31 2013-05-28 단백질 키나제 저해제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197011438A Ceased KR20190043648A (ko) 2012-05-31 2013-05-28 단백질 키나제 저해제

Country Status (11)

Country Link
US (1) US9796716B2 (enExample)
EP (1) EP2855484A4 (enExample)
JP (1) JP6175495B2 (enExample)
KR (2) KR20190043648A (enExample)
CN (1) CN104379586B (enExample)
BR (1) BR112014029718A2 (enExample)
CA (1) CA2874211A1 (enExample)
HK (1) HK1208460A1 (enExample)
IN (1) IN2014MN02338A (enExample)
RU (1) RU2678767C2 (enExample)
WO (1) WO2013177668A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833867A1 (en) * 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
CA2834528A1 (en) * 2013-11-26 2015-05-26 Pharmascience Inc. Protein kinase inhibitors
RU2674701C2 (ru) * 2014-07-07 2018-12-12 Цзянсу Хэнжуй Медицин Ко., Лтд. Аминопиридазиноновые соединения в качестве ингибиторов протеинкиназы
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
US20180179210A1 (en) * 2015-05-27 2018-06-28 Pharmascience Inc. Inhibitors of the TEC Kinase Enzyme Family
US10927087B2 (en) 2015-12-07 2021-02-23 Dic Corporation Method for producing polymerizable compound
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
CN109369654A (zh) * 2018-11-20 2019-02-22 山东大学 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
JP2024544558A (ja) * 2021-11-15 2024-12-03 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｓｒｃ阻害剤としての化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
PT1212327E (pt) * 1999-09-17 2004-01-30 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos
SK3792002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Kinase inhibitors as therapeutic agents
SK13752001A3 (sk) * 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
AUPR392301A0 (en) 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
US20040248906A1 (en) * 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
EP2526934B1 (en) * 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
WO2011046954A1 (en) * 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
JP6139782B2 (ja) * 2013-05-21 2017-05-31 チャンスー メドリューション リミテッド 置換ピラゾロピリミジン化合物、及びその薬学的に許容される塩、並びにこれらの溶媒和物、立体異性体、及び互変異性体、並びにこれらを含む医薬組成物
CN103787839B (zh) 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 合成2,3,4,5,6-五氟苯酚的方法

Also Published As

Publication number Publication date
KR20190043648A (ko) 2019-04-26
JP2015518009A (ja) 2015-06-25
WO2013177668A1 (en) 2013-12-05
EP2855484A1 (en) 2015-04-08
US9796716B2 (en) 2017-10-24
IN2014MN02338A (enExample) 2015-08-14
BR112014029718A2 (pt) 2017-06-27
KR20150015527A (ko) 2015-02-10
CA2874211A1 (en) 2013-12-05
US20150191473A1 (en) 2015-07-09
HK1208460A1 (en) 2016-03-04
RU2014145285A (ru) 2016-07-20
CN104379586A (zh) 2015-02-25
RU2678767C2 (ru) 2019-02-01
JP6175495B2 (ja) 2017-08-02
CN104379586B (zh) 2018-01-16
EP2855484A4 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
KR101972990B1 (ko) 단백질 키나제 저해제
KR101903123B1 (ko) 단백질 키나제 저해제
JP6001053B2 (ja) タンパク質キナーゼ阻害剤
CA2667487C (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP2694515B1 (en) Protein kinase inhibitors
WO2011079274A1 (en) Aminopyrimidine kinase inhibitors
JP2016510042A (ja) ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途
CA2833701A1 (en) Protein kinase inhibitors
CA2779184A1 (en) Protein kinase inhibitors
CA2813299A1 (en) Protein kinase inhibitors
CN103923066B (zh) 多靶点抗肿瘤化合物及其制备方法和应用
WO2014029007A1 (en) Protein kinase inhibitors
HK40013013A (en) Dna-pk inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T12-X000 Administrative time limit extension not granted

St.27 status event code: U-3-3-T10-T12-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220423

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220423